7210 Frederick-Banting
Suite 100
St. Laurent, QC H4S 2A1
Canada
857 412 7018
https://www.reparerx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 180
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Lloyd Mitchell Segal | Pres, CEO & Director | 913.39k | N/A | 1964 |
Dr. Michael Zinda Ph.D. | Exec. VP & Chief Scientific Officer | 641.53k | N/A | 1971 |
Dr. Maria Koehler M.D., Ph.D. | Exec. VP & Chief Medical Officer | 682.8k | N/A | 1957 |
Dr. Daniel Durocher Ph.D. | Co-Founder | N/A | N/A | N/A |
Dr. Frank Sicheri Ph.D. | Co-Founder | N/A | N/A | N/A |
Dr. Agnel Sfeir Ph.D. | Co-Founder | N/A | N/A | N/A |
Mr. Steve Forte | Exec. VP & CFO | N/A | N/A | 1979 |
Mr. Daniel Belanger | Exec. VP of Human Resource | N/A | N/A | N/A |
Mr. Cameron Black | Exec. VP of Discovery | N/A | N/A | N/A |
Dr. Kim A. Seth Ph.D. | Exec. VP & Chief Bus. Officer | N/A | N/A | N/A |
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase ½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has icense and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; and Ono Pharmaceutical Co. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in St-Laurent, Canada.
Repare Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.